Distributor inventory | Tablet

Type 2 diabetes mellitus: to improve glycaemic control in adults when diet and exercise alone or current therapy is inadequate.

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP), leading to increased glucose-dependent insulin release and reduced glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption and improves insulin sensitivity.

Oral tablet. Typically taken with meals to reduce stomach upset; swallow whole with water. Dose and frequency as prescribed by the doctor; do not stop or change dose without medical advice.

Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, metallic taste, headache, dizziness, upper respiratory tract infection

Use only in type 2 diabetes (not for type 1 diabetes or diabetic ketoacidosis). Risk of lactic acidosis with metformin—higher in severe kidney disease, dehydration, sepsis, heavy alcohol use, or hypoxia; assess renal function before and during therapy. Use caution in liver disease; vildagliptin may raise liver enzymes—monitor if symptoms of hepatitis occur. Temporarily stop metformin before/at time of iodinated contrast studies or major surgery as advised. Monitor for pancreatitis symptoms (severe abdominal pain), and for hypoglycaemia if used with insulin or sulfonylureas.

Alcohol (increases lactic acidosis risk), iodinated contrast media, carbonic anhydrase inhibitors (e.g., topiramate, acetazolamide), cimetidine, diuretics, corticosteroids, beta-agonists, ACE inhibitors, insulin and sulfonylureas (increased hypoglycaemia risk), drugs affecting renal function (e.g., NSAIDs)

Store below 25°C in a cool, dry place. Protect from moisture and direct light. Keep out of reach of children.

Galvus Met 50/500 Tablet, Zomelis Met 50/500 Tablet, Jalra M 50/500 Tablet, Vilda M 50/500 Tablet, Vildamet 50/500 Tablet